skip to primary navigationskip to content

Dr Brian Ference

Dr Brian Ference

Director of Research in Translational Therapeutics

Research themes

Population Sciences:

Research Interests

Dr. Ference graduated from Yale Medical School. He also trained in internal medicine as a clinical investigator resident in genetic epidemiology at Yale. Dr Ference then trained in cardiology and interventional cardiology at Harvard Medical School, and as a NHLBI Cardiovascular (Genetic) Epidemiology Fellow at the Brigham and Women’s Hospital and Harvard Medical School.

He then obtained a business degree in BioScience Enterprise at the Judge Business School and the Institute of Biotechnology at the University of Cambridge, UK. He subsequently earned a degree in evidence-based medicine from the International Programme in Evidence-Based Heath Care at the University of Oxford, UK, where he focused on developing methods to assess epidemiologic and genetic effect modification.

Dr Ference then returned to the States where he founded and led a biotechnology company that focused on developing novel non-parametric methods to for discovering polymorphisms that lead to differential genomic vulnerability to modifiable risk factors for cardiovascular disease.

He is currently Clinical Chief of the Division of Cardiovascular Medicine, Director of the Cardiovascular Genomic Research Center, and Chief of the Division of Translational Research and Clinical Epidemiology at Wayne State University. His current research utilizes the principles of Mendelian randomization to identify risk factors that have both a causal and a cumulative effect of the risk of disease in an attempt to identify targets for early intervention, and to model “naturally randomized trials” that attempt to frame and answer clinical questions when an actual clinical trial would be impractical or impossible to conduct.


Key Publications

Brian A Ference published latest article in European heart journal entitled Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. This article is available in PubMed with an unique identification number PMID: 29020411 and it is published in 2017. The coauthors of this article are Ference BA, Cannon CP, Landmesser U, Lüscher TF, Catapano AL, Ray KK.


Cambridge Cardiovascular logo - transparent

Logo design by Dr Ana-Mishel Spiroski and Dr Sarah Morgan.


We connect cardiovascular researchers in Cambridge.

Please follow us on Twitter for local news about research, events, funding calls, and open positions.

For inquiries about our research or the website, please contact Dr Katja Kivinen.